Geftinat

Gefitinib brought a new lease of life to the treatment of Non-Small Cell Lung Cancer (NSCLC), the first targeted therapy for NSCLC. Gefitinib spells better survival in EGFR mutated patients, and a good tolerability combined with improved quality of life has been a highlight. GEFTINAT was the first generic brand to be introduced in 2004 at a fractional price of the innovator when the market was grappling between the high priced gefitinib and conventional cytotoxics. The brand not only became a strong pillar for the company but also for the patients.

With many such novel products NATCO continues to be the torch bearer of the Indian oncology market.